Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
Oncology Department, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
Clin Interv Aging. 2021 Feb 2;16:205-212. doi: 10.2147/CIA.S294704. eCollection 2021.
Patients with cancer tend to have a high prevalence of depressive symptoms. The direct relationship between serum glycosylated hemoglobin (GHb) levels and depressive symptoms in cancer patients is still uncertain. We aimed to evaluate the association with serum GHb levels with depressive symptoms in the population (aged ≥49 years) with cancer.
Longitudinal data in 204 participants with cancer obtained from The Irish LongituDinal Study on Ageing (TILDA) were used to investigate the association of serum GHb levels with depressive symptoms.
Our results suggested a positive and significant association between serum GHb levels and depression score, independent of age, gender, body mass index (BMI), currently married, education, smoking status, drink alcohol, systolic and diastolic blood pressure (BP), physical activity, self-reported cardiovascular diseases and laboratory measurement in participants with cancer (coefficient =0.141, P<0.001; Model 2) at baseline (wave 1). Higher GHb levels did associate with higher prevalence of depressive symptoms in participants with cancer (OR=2.100, 95% CI 1.105-5.036, P=0.004; Model 2) after adjustment for these same confounding factors in wave 1 was made. Stratified analysis further showed that these significant associations were interfered by antidepressants. Sensitivity analysis showed that higher serum GHb levels in subjects with cancer were linked to higher prevalence of depression events during a follow-up of 4 years.
Our results found a significant association between elevated serum GHb levels and increased risk of depressive symptoms in the population aged ≥49 years with cancer after confounding factors were adjusted.
癌症患者往往存在较高比例的抑郁症状。血清糖化血红蛋白（GHb）水平与癌症患者抑郁症状之间的直接关系尚不确定。我们旨在评估人群（年龄≥49 岁）中血清 GHb 水平与癌症患者抑郁症状之间的相关性。
使用来自爱尔兰老龄化纵向研究（TILDA）的 204 名癌症患者的纵向数据，调查血清 GHb 水平与抑郁症状之间的关联。
我们的研究结果表明，血清 GHb 水平与抑郁评分之间存在正相关且具有统计学意义，这种相关性独立于年龄、性别、体重指数（BMI）、目前婚姻状况、受教育程度、吸烟状况、饮酒状况、收缩压和舒张压（BP）、身体活动、自我报告的心血管疾病以及参与者的实验室测量值（在基线时[第 1 波]的系数=0.141，P<0.001；模型 2）。在调整第 1 波中相同的混杂因素后，较高的 GHb 水平与癌症患者中抑郁症状的更高发生率相关（OR=2.100，95%CI 1.105-5.036，P=0.004；模型 2）。分层分析进一步表明，这些显著相关性受到抗抑郁药的干扰。敏感性分析显示，在 4 年的随访中，癌症患者的血清 GHb 水平升高与抑郁事件的更高发生率相关。
在调整混杂因素后，我们的研究结果发现，血清 GHb 水平升高与≥49 岁癌症人群中抑郁症状的发生风险显著相关。
